Arkadios Wealth Advisors Has $1.07 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Arkadios Wealth Advisors increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 398.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,040 shares of the biopharmaceutical company’s stock after acquiring an additional 1,631 shares during the period. Arkadios Wealth Advisors’ holdings in Regeneron Pharmaceuticals were worth $1,071,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. World Investment Advisors boosted its position in shares of Regeneron Pharmaceuticals by 51.7% during the 2nd quarter. World Investment Advisors now owns 549 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 187 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $467,000. Evergreen Wealth Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 84.6% during the 2nd quarter. Evergreen Wealth Management LLC now owns 10,436 shares of the biopharmaceutical company’s stock valued at $5,479,000 after acquiring an additional 4,783 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $31,000. Finally, New York Life Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 0.8% during the 2nd quarter. New York Life Investment Management LLC now owns 14,353 shares of the biopharmaceutical company’s stock valued at $7,535,000 after acquiring an additional 113 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent analyst reports. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company boosted their price target on shares of Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a research report on Wednesday. Bank of America boosted their price target on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research report on Wednesday. Finally, Citigroup boosted their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $802.36.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of NASDAQ REGN opened at $651.80 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $883.15. The company has a market cap of $69.08 billion, a PE ratio of 15.61, a P/E/G ratio of 2.03 and a beta of 0.31. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average of $581.80 and a two-hundred day moving average of $565.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the previous year, the firm posted $12.46 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.